MedTrace Logo

Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia

NCT00543608 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2009-02-13

No results posted yet for this study

Summary

The purpose of this study is to compare the clinical cure rates of two dosing regimens of iclaprim with vancomycin (every 12 hours \[q12h\]) in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or health-care-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.

Conditions

  • Hospital-Acquired Pneumonia
  • Ventilator-Associated Pneumonia
  • Health-Care-Associated Pneumonia

Interventions

DRUG

iclaprim

DRUG

vancomycin

Sponsors & Collaborators

  • Arpida AG

    lead INDUSTRY

Principal Investigators

  • David Willms, MD · Sharp HealthCare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-04-30
Completion
2009-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00543608 on ClinicalTrials.gov